Effects of combined metformin and cabergoline versus metformin alone on inflammatory markers in Iraqi patients with PCOS and hyperprolactinemia: a randomized clinical trial
Inas Naser Hamad, Sinaa Abdul Amir Kadhim, Mohammad Bassim, Swadi Asma, Fawzi Hayder Adnan · 2026
Read Effects of combined metformin and cabergoline versus metformin alone on inflammatory markers in Iraqi patients with PCOS and hyperprolactinemia: a randomized clinical trial by Inas Naser Hamad, Sinaa Abdul Amir Kadhim, Mohammad Bassim, Swadi Asma, Fawzi Hayder Adnan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13389816.txt.
Description
Inas Hamad and four co-authors test two drugs alone and together for inflammation in women with polycystic ovary syndrome and high prolactin, in a trial from 2026. The syndrome is a common metabolic condition in women of childbearing age, often with weight gain and low-grade inflammation. Both drugs are already used in this setting.
Seventy-five women in Iraq were split into three arms for single or combined therapy. Either drug alone left one antibody marker unchanged, but the pair cut it, which suggests synergy. The pair also cut a hormone antibody and a key inflammatory signal more strongly. The authors back combined use, with larger trials still needed.
Catalog record
| CREATOR | Inas Naser Hamad, Sinaa Abdul Amir Kadhim, Mohammad Bassim, Swadi Asma, Fawzi Hayder Adnan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |